Summary Background The RTS, S/AS01 malaria vaccine targets the circumsporozoite
protein, inducing antibodies associated with the prevention of Plasmodium falciparum …

Summary Background The RTS, S/AS01 E candidate malaria vaccine is being developed for
immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 …

Background A malaria vaccine could be an important addition to current control strategies.
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …

Background The candidate malaria vaccine RTS, S/AS01 reduced episodes of both clinical
and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing …

Abstract Background The RTS, S malaria vaccine is currently undergoing phase 3 trials.
High vaccine-induced antibody titres to the circumsporozoite protein (CSP) antigen have …

Background The efficacy of RTS, S/AS01 as a vaccine for malaria is being tested in a phase
3 clinical trial. Early results show significant, albeit partial, protection against clinical malaria …

Summary Background RTS, S/AS01E is the lead candidate malaria vaccine. We recently
showed efficacy against clinical falciparum malaria in 5–17 month old children, during an …

Background Development of an effective malaria vaccine could greatly contribute to disease
control. RTS, S/AS02A is a pre-erythrocytic vaccine candidate based on Plasmodium …

Background Plasmodium falciparum malaria is a pressing global health problem. A previous
study of the malaria vaccine RTS, S (which targets the circumsporozoite protein), given with …

Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …